FDA Solicits Databases To Track Infrequent, Rare Drug AEs
This article was originally published in The Tan Sheet
FDA is looking to establish cooperative agreements for databases that track drug adverse events in the U.S., a request for funding applications published in the Federal Register April 4 states.
You may also be interested in...
FDA is considering examining more extensive ways to inform consumers about the dangers of acetaminophen as well as techniques to limit access to OTC drugs containing the analgesic ingredient.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning